Pancreatic ductal adenocarcinoma (PDAC) is considered to be a highly immunosuppressive and heterogenous neoplasm which has extremely poor survival. Despite improved knowledge regarding the genetic background of the tumor and better understanding of the tumor microenvironment, immune checkpoint inhibitor therapy (targeting CTLA-4, PD-1, PD-L1), which has shown effect in other solid tumors, has not been very successful against PDAC.
Introduction
Pancreatic cancer is a devastating disease with very poor outcomes. In spite of concerted efforts to develop effective therapeutic strategies, the five-year survival rate of the patients diagnosed with this disease is a mere 7% 1, 2 . High rates of tumor relapse, therapeutic resistance and metastatic spread of the tumor contribute to these dismal statistics 3, 4 . Compounding this, the pancreatic tumor is largely immune evasive, making these tumors resistant to immune checkpoint inhibitor therapies (with anti-PD1, anti-PDL1 and anti-CTLA4 therapy) that have shown remarkable benefit in other tumors 5, 6 .
Resistance to these immune therapies is predominantly due to the presence of an extensive fibroinflammatory and desmoplastic stroma with a rich extracellular matrix (ECM). Together, these components of the tumor provide an immune suppressive microenvironment that prevents the infiltration of anti-tumor immune cells like CD8+ T-cells 7, 8 . Targeting the stromal component (like activated stellate cells, cancer-associated fibroblasts or the hyaluronan-rich extracellular matrix) has shown sensitization of pancreatic tumors to standard chemotherapy over recent years [9] [10] [11] [12] . However, it is acknowledged that an anti-stromal therapy by itself is likely to result in a more aggressive tumor by relieving pressure on blood vessels and promoting metastasis 13 . Thus, a treatment strategy that can deplete the stroma while eradicating the tumor cells in order to prevent metastatic spread is ideal for this devastating disease.
While the role of stellate cells in secretion of the robust ECM is well-known 7 , how the ECM may contribute to the immune suppressive microenvironment within pancreatic tumor remains an enigma.
Studies have shown that infiltration of CD8+ T-cells is associated with better patient outcomes 14, 15 .
Similarly, depletion of CD4+ T-cells in pancreatic cancer mouse models has been shown to result in decreased infiltration of several tumor-promoting myeloid cell population like macrophages and immature myeloid cells or myeloid-derived suppressor cells (MDSCs), indicating that the immune cell behavior within the tumor microenvironment is a complex interaction between different cell types 16 17 .
In patients with pancreatic cancer, an immune response is typically mediated by CD8+ T-cell infiltration.
However, a large number of these cells become trapped in the peritumoral stroma and do not reach the tumor to elicit an anti-tumor response 18 . Migration of infiltrating T-cells is typically guided by stromal chemokines and ECM proteins 19, 20 . Additionally, T-cells use the ECM fibers to migrate to tumor cells whether by ameboid-like contact guidance or using integrin-based adhesion 20, 21 . Thus, remodeling of ECM is likely to have a profound effect on T-cell infiltration and function in pancreatic cancer 22 .
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The ECM of pancreatic tumors is primarily composed of glycosaminoglycans like hyaluronan (HA). HA is a polymer of glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). Synthesis of HA is orchestrated by HA synthases (HAS 1-3). These enzymes require UDP-GlcNAc as one of the primary substrates for synthesis of HA 23, 24 . In a cell, UDP-GlcNAc is synthesized via the hexosamine biosynthesis pathway (HBP), a shunt pathway of glycolysis that utilizes glutamine and glucose to make this nucleic acid sugar 25, 26 . Since HBP is also a nutrient sensing pathway, the synthesis of HA in these tumors is tightly coupled with the metabolic status of the cells. The rate-limiting enzyme of this pathway is glucosamine-fructose amidotransferase (GFAT1/2), which is responsible for controlling the flux of metabolites through this pathway. The HBP is highly utilized in a number of cancers, and its inhibition by either targeting GFAT1/2 or by preventing utilization of glutamine (using a glutamine analog 6-diazo-5-oxo-L-norleucine or DON) results in tumor regression [27] [28] [29] .
UDP-GlcNAc is a major metabolite that is used in cellular glycosylation reactions. Decreased UDPGlcNAc production can induce ER stress in the cells by inhibiting these reactions 30 . Further, since UDP-GlcNAc is used by O-GlcNAc transferase (OGT) to glycosylate and regulate a large number of oncogenic proteins (like Myc), inhibition of UDP-GlcNAc production will affect the survival of the cancer cells 31 . Consistent with this, previous studies from our laboratory have shown that HBP-fueled UDPGlcNAc synthesis can be used by OGT to drive tumor growth and self-renewal 32 33 . Thus, HBP forms an integral metabolic node, inhibition of which will affect the tumor and its microenvironment alike.
While the role of HBP in cancer cell survival is being studied by several groups, whether HBP can be targeted genetically or pharmacologically to remodel the ECM, and thus make the immune evasive pancreatic tumor to immune therapy, has not been studied before. Since the hexosamine biosynthesis pathway is dependent on glucose uptake and glutamine equally, inhibition of glutamine utilization by using glutamine analogs like azaserine and 6-diazo-5-oxo-L-norleucine (DON) has been used over the years to target this pathway. Even though studies have shown that DON may have pleiotropic effects 34 , it was used clinically as an anti-tumor agent 35 . DON was successfully used in five phase 2 clinical trials 34 , leading to disease stabilization. However, in spite of showing promise, DON was abandoned clinically as an anti-tumor agent. With the recent knowledge that tumor microenvironment is an integral component that drives progression of the tumors, there has been a renewed interest in reviving DON as an anti-tumor agent. Since recent evidence showed that a broad-spectrum antagonist of glutamine is more effective in inducing tumor regression than selective inhibition of a single glutamine-utilizing enzyme 36 , DON is being re-evaluated as a potential therapy in a number of cancers specifically in combination with other chemotherapeutic agents 37, 38 . Therapeutic strategies using DON against glutamine dependent tumors have also been proposed 38 .
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Colony forming assay S2-VP10 cells were pretreated with DON for 24 hours. Cells were counted and plated at a density of 10K,1K and 100 cells per well in both treatment and control group respectively. Colonies were counted after 4 days of plating. The results represented are from 1000 cells per well but the result is similar across different dilutions.
Immunohistochemistry
Tissues were deparaffanized by heating at 56 Slides were then mounted with paramount and dried overnight and imaged by a bright field microscope.
GFPT1 antibody (14132-1-AP) was purchased from protein tech and used at a dilution of 1:200. α-SMA (ab5694), CD4 (ab183685), CD8 (ab22378) and PDL1 (ab80276) was purchased from Abcam and were used at a dilution of 1:200,1:1000,1:200 and 1:50 respectively. For CD4 and CD8 antibody citrate buffer was used for antigen retrieval. Ki-67 SP6 antibody was purchased from Thermo Fisher Scientific and was used at a dilution of 1:200.
All experiments were done according to the protocol approved by Institutional Animal Care and Use Committee (IACUC) at University of Miami. Female athymic nude (nu/nu) mice between the ages of 4-6 weeks were used for in vivo experiments. For subcutaneous experiments 500,000 S2VP10 cells were implanted in the right flank of athymic nude mice. Corning® Matrigel® Growth Factor Reduced (GFR)
Basement Membrane Matrix and 1X PBS at a ratio of 1:1 were used as a suspension medium for the cells. Tumors were allowed to reach a size of 100mm3 and then the treatment was started. Mice were given DON at a dose of 1mg/kg/5days a week for 4 weeks. At the end of the 4 th week mice were 7 sacrificed and the tumor weight and volume were noted. Tissues were flash frozen for further experiments.
C57/BL6 mice between the ages of 4-6 weeks were used for orthotopic implantation of KPC and CAF cells. 1000KPC and 9000 CAF's implanted orthotopically in 100% Corning® Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix. Tumors were allowed to grow for 2 weeks after which the mice were randomized and treatment was started. DON was given at a dose of 1mg/kg/3days a week i.p and 2 DG was given at a dose of 1000mg/kg/day i.p. for 4 weeks after which the mice were sacrificed. Orthotopic tumors were harvested, dimensions were noted and metastasis was evaluated.
Blood for CTC isolation was collected via cardiac puncture and blood from 3 mice per group was pooled for CTC.
For evaluating the combinatorial effect of DON and PD1 on tumor growth C57/BL6 mice between the ages of 4-6 weeks were used. 1000KPC and 9000 CAF's implanted orthotopically in 100% Corning®
Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix. Tumors were allowed to grow for 2 weeks after which the mice were randomized and treatment was started. DON was given at a dose of 0.5mg/kg/3days a week and PD1 was given at a dose of 100μgm per mice at day 15,17 and 19 after starting DON treatment. DON was given for 4 weeks after which the mice were sacrificed and tumor was harvested and metastasis was evaluated.
CD-8 knockout mice (CD-8KO) were purchased from Jackson Laboratory. 1000 KPC and 9000 CAF cells were implanted orthotopically in 100% Corning Matrigel Growth Factor Reduces Basement
Membrane Matrix CD-8KO mice. Tumors were allowed to form for 2 weeks after which the mice were randomized into control and treatment group. DON was started at week 3 post-surgery at a dose of 0.5mg/kg 3 times a week. Mice were monitored daily for morbidity or mortality and a survival curve was plotted.
Isolation of Circulating Tumor Cells
Circulating tumor cells were isolated according to 43 . Briefly, 0.5 ml of blood was collected from animals in the control and DON treated group in EDTA coated tubes. The blood was passed through the Circulogix FaCTChecker system and captured on the system's filter cartridges mounted on slides. Captured cells were stained with fluorescent tagged antibodies against CD45 and CK19. The CD45-CK19 + fraction was quantitated from each group of animals.
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Multiplexed cytometric bead array
KPC and CAF cells were pre-treated with DON for 24 hours. 100,000 cells were plated in Corning®
Transwell® polycarbonate membrane cell culture inserts in the following manner-Cells placed in the chamber have the letter "C" after them and the cells plated on the plate have the letter "P" after them.
The treatment groups were KPC(C)+CAF(P), DON KPC(C)+CAF(P), DON CAF(C)+KPC(P) DON KPC (C)+DON CAF (P) and media only. Cells were allowed to be in coculture for 24 hours. Conditioned
Media was collected post incubation. Mouse Inflammation Kit (BD 552364) was used and the experiment was performed according to the manufacturer's instructions.
Flow-cytometry for infiltrated immune cells
Tumor samples harvested from mice were placed in RPMI until they were ready to be processed.
Tumors were minced into tiny pieces and then they were digested with Collagenase IV at 37 degree for 1-3 hours. After the tissue has been digested they were passed through a 40μm nylon filter. The tissue was then spun at 500g for 5 mins and was then resuspended in 1ml of flow buffer (0.5% Bovine Serum Albumin,2mM EDTA, 1% Penicillin-Streptomycin in 500mL PBS) The tubes were then spun again at 500g for 5 mins. 100μl of cytofix-cytoperm buffer was added to the pellet and the cells were allowed to fix for an hour at room temperature. After 1 hour, the cells were then washed with 1 ml of FACS buffer and then centrifuged at 500g for 5 mins. The supernatant was then discarded and the cells were 
Boydon Chamber Invasion Assay
24 well chamber inserts (Corning BioCoat) were hydrated in serum-free medium for 2-3 hours: the bottom of the chamber wells contrainted the attractant (10% FBS contraining DMEM) 50,000 cells were plated on the top of the insert. 24 hours later, cells that did not invade were scrubbed from the top chamber via a cotton swab and the invaded cells were fixed in methanol and stained with crystal violet.
Invases cells were counted my microscopy.
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Migration Assay
The migration assay was conducted by Electric Cell-substrate Impedence Sensing (ECIS) (Applied Biophysics) and performed as described in Banerjee et al, 2014 44 .
Tetracyclie inducible GFAT knockdown cell line
For the generation of tet inducible GFAT knockdown cell line. S2VP10 was selected as a parent cell line. shRNA oligoes for GFPT1 was purchased from idt and the cell lines were made according to the protocol as described by Wiederschain, D et al 45 and Wee et al 46
Statistics
All in vitro experiments were performed in 3 independent runs and the values were expressed as the mean + SEM. Students t tests were used to determine the significance and P values of less than 0.05
were considered statistically significant.
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Results
Hexosamine Biosynthesis Pathway is overactivated in pancreatic cancer
Since chronic pancreatitis is a well-known risk factor for pancreatic ductal adenocarcinoma 47 , we studied the expression of GFAT1/2 (alias GFPT1/2) as well as the other enzymes in this pathway in caerulein-induced chronic pancreatitis as well as in KPC pancreatic cancer mouse model during tumor progression. Our results showed that these enzymes were overexpressed upon induction of pancreatitis ( Figure 1A ) as well as during pancreatic tumor progression ( Figure 1B ). In addition, expression of GFAT1 was also increased in the ductal cells of the pancreatic adenocarcinoma when observed in a tumor tissue microarray ( Figure 1C ). Further, an analysis of The Cancer Genome Atlas (TCGA) database showed that this pathway was overexpressed in 35.7% of the 176 pancreatic cancer patients in the database at both the RNA and protein level ( Figure 1D ). To study if GFAT1 was expressed both in the tumor and stroma, we performed immunohistochemistry with anti-alpha SMA and anti-GFAT1 antibody. Our results showed that GFAT1 is predominantly expressed in the tumor cells.
As seen in the figure ( Figure 1E , F), GFAT1 did not co-stain with alpha SMA in the mouse KPC tumors ( Figure 1E ) or in the human tumors ( Figure 1F ). Since GFAT1 is the rate-limiting step of this pathway, we focused our study on this particular enzyme.
GFAT1 contributed to aggressive biology of pancreatic cancer by regulating self-renewal and metastasis.
A mark of an aggressive tumor is its ability to metastasize and its potential to relapse after treatment.
These are dependent on the genes that regulate self-renewal. Our previous results 32 show that OGT, an enzyme dependent on UDP-GlcNAc and thus HBP, was instrumental in regulating self-renewal in pancreatic cancer via its effect on Sox2. Our results showed that inhibition of GFAT1, the rate-limiting enzyme of HBP, using siRNA resulted in inhibition of a number of self-renewal genes like Sox2, Oct4
and KLF4 in the pancreatic cancer cell lines MIA-PaCa2 and S2VP10 ( Figure 2A ). Since GFAT1 activity is dependent on availability of glutamine, we next blocked glutamine utilization with DON. Our studies showed that treatment of pancreatic cancer cell lines MIA-PaCa2 and S2VP10 with DON resulted in decreased expression of self-renewal genes as seen with GFAT siRNA (Supplementary Figure 1A) . To study if the inhibition of HBP by blocking glutamine utilization with DON resulted in decreased clonogenicity (a surrogate assay for self-renewal), we performed a colony forming assay on
results showed that treatment with DON resulted in decreased colony formation showing that glutamine utilization by HBP was instrumental in decreasing self-renewal in pancreatic cancer cells ( Figure 2B ).
This observation was further validated in the pancreatic cancer cell line L3.6PL (Supplementary Figure   1B ). These observations indicated that DON suppressed self-renewal ability of pancreatic cancer cells.
Our previously published data show that DON affected tumor cell proliferation 33 . Our current study showed that treatment with DON decreased viability of primary KPC cells while it did not have any effect on the viability of primary cancer-associated fibroblasts in vitro ( Figure 2C ), indicating that within a tumor DON had differential effect on the cellular components.
Since HBP affects the activity of OGT, which in turn is instrumental in regulating the metastatic property To rule out off-target effects of small molecule DON, we next constructed a tet-driven shGFAT1 and transfected metastatic pancreatic cancer cell line S2VP10 to generate a tet-shGFAT1 cell line. These cells were implanted orthotopically in athymic nude mice. Ten days after implantation, GFAT1 expression was turned off by adding tetracycline to the chow. Animals were followed for an additional 30 days. As seen with DON, there was a significant reduction in end-of-study tumor volume ( Our study showed that while there was a significant decrease in a number of collagen synthesis genes along with expression of genes involved in other structural components of ECM ( Figure 4D ), there was a more profound effect on the ECM remodeling proteases ( Figure 4E ). This indicated that there was an extensive ECM remodeling in the pancreatic tumor microenvironment. In addition, there was also a significant alteration of expression of a number of cell-cell and cell-ECM adhesion molecules (Supplementary Figure 3D ).
It is well-known that the tumor and stromal cells remodel the ECM not only via synthesis of basement membrane constituents, but also through cytokine secretion. To evaluate this, we next set up the coculture as described in Supplementary Figure 3C , and estimated the secreted cytokine profile using a cytometric bead array. Upon co-culture in a transwell, in which CAFs were treated with DON, IFNγ and IL6 were observed to be significantly altered by DON treatment, while only IL27 showed a significant decrease when only KPC cells were treated with DON in the co-culture ( Figure To study if DON was still an effective anti-tumor compound in the absence of CD8+ T-cells, we next implanted KPC001 and CAF cells orthotopically in the pancreas of CD8KO mice in a ratio of 1:9. The tumors were allowed to grow for two weeks before they were randomized to DON (0.5mg/kg/3 days a week) treatment or control groups. Treatment was continued for 30 days and survival analysis was performed. Our results showed that survival of DON-treated animals in the CD8KO mice was not different from the untreated animals ( Figure 5E ). Further, necropsy of animals across both groups showed no difference in tumor volume ( Figure 5F ). These results suggested that efficacy of DON in an immune competent syngeneic pancreatic cancer model was largely dependent on CD8+ T-cells. 
Discussion
Glutamine is one of the metabolites that is essential for growth and proliferation of cancer cells. It fuels a number of biosynthetic reactions in a cancer cell 55, 56 . Consistent with this, glutamine-utilizing enzymes like GFAT1 are overexpressed in most cancers, including pancreatic cancer as reported by our lab (Figure 1 ) and others 57, 58 . Pancreatic cancer cells have been shown to utilize glutamine in a non-canonical fashion to support proliferation via redox homeostasis 39, 59-62 . As glutamine metabolism is dispensable for non-malignant cells, yet has a critical role in PDAC survival, it is an ideal candidate for therapeutic targeting.
Among glutamine-utilizing enzymes, glutamine-fructose amidotransferase 1 (GFAT1) is the rate-limiting enzyme for the hexosamine biosynthesis pathway (HBP). This pathway is a shunt pathway of glycolysis that utilizes fructose-6 phosphate from glycolysis and glutamine to synthesize UDP-GlcNAc, a nucleotide sugar that is essential for glycosylation reactions. Apart from N-glycosylation and OGlcNacylation, UDP-GlcNAc is also a substrate for hyaluronan synthesis. Hyaluronan is a key component of the extracellular matrix and therefore, inhibition of HBP is likely to affect the extracellular . In fact, the stroma has been proposed to be a "restraining" mechanism of the host cells 13 . However, preclinical studies from our lab as well as others have shown that the tumor microenvironment can be targeted only when the targeting agent can affect both tumor epithelial cells as well as stromal cells
. Thus, treatment with DON, which increases anti-tumor activity and remodels the ECM to promote infiltration of cytotoxic T-cells in combination of anti-PD1 therapy, is a promising strategy to combat pancreatic cancer. However, even though tumor cells responded to DON treatment, the stromal fibroblasts (or CAFs) were resistant to DON treatment, as seen by the viability assay done in vitro ( Figure 2C ). This was an interesting observation since athymic nude mice are immunocompromised, and if DON was facilitating its effect solely by altering the immune landscape, we would not have seen such an astounding effect on tumor regression in these mice. However, DON also has a profound effect on cancer cells as it prevents glutamine utilization (since it is a glutamine analog). It is possible that in our in vivo experiment 
Conclusion
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a highly immunosuppressive and heterogeneous neoplasm 6, 74 . Despite improved knowledge regarding the genetic background of the tumor and better understanding of the tumor microenvironment, immune checkpoint inhibitor therapies (using CTLA-4, PD-1, PD-L1), that have shown effect in other solid tumors, have not been very successful in PDAC. Thus, novel therapeutic strategies that can make PDAC more amenable to immune therapy are urgently needed. In this context, our study is extremely timely as it reveals how specific metabolic pathways can be targeted in cancer cells to overcome immune resistance and sensitize the tumors to anti-PD1 like therapy options that have worked extremely well in other cancers.
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DON decreased PDL1 expression as seen by immunohistochemistry image (C). Treatment with DON
decreased HA and collagen in the syngeneic tumors, however the decrease of these ECM components in the combination group was marginal (D). 
